MiNK Therapeutics Inc.
(INKT)
undefined
undefined%
At close: undefined
Company Description
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.
Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
The company was formerly known as AgenTus Therapeutics, Inc.
MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
MiNK Therapeutics Inc.
| Country | United States |
| IPO Date | Oct 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Dr. Jennifer S. Buell Ph.D. |
Contact Details
Address: 149 Fifth Avenue New York, New York United States | |
| Website | https://minktherapeutics.com |
Stock Details
| Ticker Symbol | INKT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001840229 |
| CUSIP Number | 603693102 |
| ISIN Number | US6036931029 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jennifer S. Buell Ph.D. | President, Chief Executive Officer & Director |
| Christine M. Klaskin | Treasurer |
| Dr. Garo H. Armen Ph.D. | Executive Chairman |
| Joy Zhou Ph.D. | Vice President & Head of CMC |
| Robert Foster | Director of Legal & Business Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 09, 2024 | 4 | Filing |
| Dec 09, 2024 | 3 | Filing |
| Dec 06, 2024 | PRE 14A | Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Dec 03, 2024 | 4 | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 8-K | Current Report |